PMID-37969642 – CV Effects GnRH Antagonists vs Agonists Prostate Cancer
Nelson AJ et al. "Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer: A Systematic Review and Bayesian Network Meta-Analysis," JACC: CardioOncology, 2023;5(5):627-638. doi:10.1016/j.jaccao.2023.05.011
Quick Reference
| Property | Value |
|---|---|
| PMID | 37969642 |
| DOI | 10.1016/j.jaccao.2023.05.011 |
| Year | 2023 |
| Journal | JACC: CardioOncology |
| Study Type | Systematic Review + Bayesian Network Meta-Analysis |
| Evidence Level | I |
| Sample | 4,248 participants across included trials |
| Peptide(s) Studied | GnRH antagonists vs GnRH agonists |
Key Findings
- Systematic review with Bayesian network meta-analysis of 4,248 prostate cancer patients on androgen deprivation therapy
- Major adverse cardiovascular events (MACE) occurred in 2.9% of patients on GnRH antagonists vs 4.8% on GnRH agonists — a clinically significant absolute risk reduction
- The Bayesian approach provided probability estimates for superiority, strengthening confidence in the cardiovascular safety advantage of antagonists
- Risk reduction was most pronounced in patients with pre-existing cardiovascular disease at baseline
- GnRH antagonists suppress FSH more completely than agonists; FSH receptors on endothelial and adipose tissue may mediate the cardiovascular risk differential
- Published in JACC: CardioOncology, a high-impact subspecialty journal, lending clinical authority to the findings
Study Design
Systematic review with Bayesian network meta-analysis. Included RCTs and prospective observational studies comparing GnRH antagonists to agonists in prostate cancer patients. Primary outcome was MACE. Bayesian framework allowed estimation of probability of benefit rather than binary significance testing.
Limitations
- Included both RCTs and observational studies, introducing heterogeneity in study quality
- MACE definitions varied across studies
- Most antagonist data from degarelix; newer oral antagonists (relugolix) had limited data at the time of analysis
- Bayesian priors selection may influence results, though sensitivity analyses were performed
Clinical Relevance
This is the most comprehensive cardiovascular safety analysis of GnRH antagonists vs agonists to date. The MACE rate of 2.9% vs 4.8% provides a concrete, patient-relevant safety metric for clinical decision-making. Practitioners managing prostate cancer patients — especially those with cardiovascular comorbidities — should preferentially consider GnRH antagonists. This evidence is critical for informed consent discussions about ADT cardiovascular risks.
Related
#research #systematic-review #evidence-level-I #cancer